Nothing Special   »   [go: up one dir, main page]

DE69005165D1 - Medicament containing a pharmaceutically acceptable carrier and the compound of the structure (7-alpha, 17-alpha) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -ene-20-yne-3 -one contains. - Google Patents

Medicament containing a pharmaceutically acceptable carrier and the compound of the structure (7-alpha, 17-alpha) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -ene-20-yne-3 -one contains.

Info

Publication number
DE69005165D1
DE69005165D1 DE90200574T DE69005165T DE69005165D1 DE 69005165 D1 DE69005165 D1 DE 69005165D1 DE 90200574 T DE90200574 T DE 90200574T DE 69005165 T DE69005165 T DE 69005165T DE 69005165 D1 DE69005165 D1 DE 69005165D1
Authority
DE
Germany
Prior art keywords
alpha
compound
pregn
hydroxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE90200574T
Other languages
German (de)
Other versions
DE69005165T2 (en
Inventor
G A J M T Sas
Doornum E M Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nv Arnheim/arnhem Nl
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19854317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69005165(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv Arnheim/arnhem Nl, Akzo NV filed Critical Akzo Nv Arnheim/arnhem Nl
Application granted granted Critical
Publication of DE69005165D1 publication Critical patent/DE69005165D1/en
Publication of DE69005165T2 publication Critical patent/DE69005165T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7 alpha ,17 alpha )-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, characterized in that the said compound is crystalline pure and completely or virtually completely free from the other crystalline form.
DE90200574T 1989-03-18 1990-03-12 Medicament containing a pharmaceutically acceptable carrier and the compound of the structure (7-alpha, 17-alpha) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -ene-20-yne-3 -one contains. Expired - Lifetime DE69005165T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8900673 1989-03-18

Publications (2)

Publication Number Publication Date
DE69005165D1 true DE69005165D1 (en) 1994-01-27
DE69005165T2 DE69005165T2 (en) 1994-05-05

Family

ID=19854317

Family Applications (1)

Application Number Title Priority Date Filing Date
DE90200574T Expired - Lifetime DE69005165T2 (en) 1989-03-18 1990-03-12 Medicament containing a pharmaceutically acceptable carrier and the compound of the structure (7-alpha, 17-alpha) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -ene-20-yne-3 -one contains.

Country Status (17)

Country Link
US (1) US5037817A (en)
EP (1) EP0389035B1 (en)
JP (2) JP3139709B2 (en)
KR (1) KR0183401B1 (en)
AT (1) ATE98490T1 (en)
AU (1) AU625083B2 (en)
CA (1) CA2011452C (en)
DE (1) DE69005165T2 (en)
DK (1) DK0389035T3 (en)
ES (1) ES2062292T3 (en)
FI (1) FI94865C (en)
HK (1) HK1002019A1 (en)
IE (1) IE63051B1 (en)
MX (1) MX9203787A (en)
NZ (1) NZ232946A (en)
PT (1) PT93488B (en)
ZA (1) ZA901674B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA941464B (en) * 1993-03-05 1994-09-27 Akzo Nv Use of pregnane derivative
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
IL123984A (en) 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmaceutical dosage units comprising tibolone and a pharmaceutically acceptable carrier
PL197870B1 (en) * 1998-10-16 2008-05-30 Organon Nv HIGH PURITY COMPOSITION COMPRISING (7α,17α)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
CN101543500A (en) * 1999-03-18 2009-09-30 基因实验室技术公司 Dhea composition and method
TWI265167B (en) * 1999-11-29 2006-11-01 Akzo Nobel Nv 3-methylene steroid derivatives
US20040229854A1 (en) * 2000-11-28 2004-11-18 Pieter Haan De Immediate release dosage form for HRT
GB0125061D0 (en) * 2001-10-18 2001-12-12 Norton Healthcare Ltd Pharmaceutical composition
DK1444247T3 (en) * 2001-10-18 2007-09-24 Norton Healthcare Ltd tibolone formulations
KR20040073572A (en) * 2002-01-22 2004-08-19 악조 노벨 엔.브이. Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
CN1324041C (en) * 2003-04-01 2007-07-04 上海迪赛诺医药科技开发有限公司 Preparation method of tibolong crystal type I
KR20050038590A (en) * 2003-05-23 2005-04-27 엔.브이. 오가논 Immediate-release pharmaceutical dosage form comprising polymorphous tibolone
EP1883648A1 (en) * 2005-05-23 2008-02-06 Newchem S.p.A. Process for the preparation of pure crystalline tibolone
EP1821571A1 (en) * 2006-02-15 2007-08-22 Oticon A/S Loop antenna for in the ear audio device
ITMI20130120A1 (en) * 2013-01-25 2014-07-26 Ind Chimica Srl PROCESS FOR PREPARATION IN THE CRYSTAL FORM OF TIBOLONE, (7ALFA, 17ALFA) -17-HYDROSSI-7-METHYL-19-NORPREGN-5 (10) -EN-20-IN-3-ONE
DK3452019T3 (en) 2016-05-04 2021-09-06 Novalon S A USE OF SUGAR ALCOHOLS IN TIBOLON COMPOSITIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE665514A (en) * 1964-06-16
US4933168A (en) * 1975-05-27 1990-06-12 Syntex Pharmaceuticals International Limited Stable, crystalline flunisolide
US4273710A (en) * 1979-05-21 1981-06-16 Syntex Corporation Process for preparing flunisolide
US4391755A (en) * 1982-01-18 1983-07-05 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
US4447426A (en) * 1982-01-18 1984-05-08 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators

Also Published As

Publication number Publication date
ZA901674B (en) 1990-12-28
NZ232946A (en) 1991-08-27
PT93488B (en) 1996-02-29
MX9203787A (en) 1992-07-01
CA2011452C (en) 1999-05-25
KR900013950A (en) 1990-10-22
DK0389035T3 (en) 1994-02-14
FI94865B (en) 1995-07-31
FI901328A0 (en) 1990-03-16
EP0389035A1 (en) 1990-09-26
DE69005165T2 (en) 1994-05-05
KR0183401B1 (en) 1999-05-01
HK1002019A1 (en) 1998-07-24
JP2001139473A (en) 2001-05-22
ES2062292T3 (en) 1994-12-16
US5037817A (en) 1991-08-06
JPH0347195A (en) 1991-02-28
ATE98490T1 (en) 1994-01-15
PT93488A (en) 1990-11-07
CA2011452A1 (en) 1990-09-18
AU5139490A (en) 1990-09-20
JP3139709B2 (en) 2001-03-05
IE900709L (en) 1990-09-18
IE63051B1 (en) 1995-03-22
FI94865C (en) 1995-11-10
AU625083B2 (en) 1992-07-02
EP0389035B1 (en) 1993-12-15

Similar Documents

Publication Publication Date Title
DE69005165D1 (en) Medicament containing a pharmaceutically acceptable carrier and the compound of the structure (7-alpha, 17-alpha) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -ene-20-yne-3 -one contains.
BR1100860A (en) Compound, anti-inflammatory drug, pharmaceutical composition, epimer r and epimer s of the compound
ATE211387T1 (en) ORAL 1ALPHA-HYDROXYPREVITAMIN D
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
CA2004239A1 (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma, and pharmaceutical compositions useful in such treatment
AU1578688A (en) Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
MY101784A (en) Novel pharmacological compounds
IL86423A0 (en) Pharmaceutical compositions for the treatment of alzheimer's disease
NO166281C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE 1,1-DISUBSTITUTED CYCLOPROPANDER DERIVATIVES.
LV10268A (en) Therapeutically active benzimidazole and its retention
IT9019112A1 (en) PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR THE ORAL ADMINISTRATION OF CALCITONIN
IT8219482A0 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ORAL CAVITY DISEASES.
ITRM920535A0 (en) PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION THROUGH THE MUCOSA.
ATE145333T1 (en) ORAL DRUGS CONTAINING HIRUDIN
FR2685204B1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TRANSCUTANEOUS ADMINISTRATION OF FENFLURAMINE.
IT1244562B (en) AGENT FOR THE PREVENTION AND TREATMENT OF CRYSTALLINE OPACITY.
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
GB2185478B (en) Novel e-valerolactam, pharmacologically active compositions thereof, processes for the preparation thereof and their medical use
MX9205204A (en) PHARMACEUTICAL COMPOSITION COMPRISING ANTAGONIST COMPOUNDS OF THE 5-HYDROXITRIPTAMINE RECEPTOR
ITRM910432A0 (en) DEVICE FOR THE ENDO AND EXORETAL APPLICATION OF PHARMACOLOGICAL, MEDICINAL AND REFRESHING SUBSTANCES.
IT8919204A0 (en) COMPOSITION FOR THE PREVENTION AND TREATMENT OF PERIODONTOPATTA.
ITRM920930A1 (en) USE OF GLUTATIONE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR ANTI-VIRAL ACTIVITIES.
ITMI913461A1 (en) THERAPEUTIC COMPOSITIONS SUITABLE FOR RECTAL ADMINISTRATION CONTAINING ONE OR MORE THIOESTERS OF GLUTATIONE AS THE ACTIVE INGREDIENT
IT212642Z2 (en) IMPROVEMENT OF THE INJECTION CONTROLLER OF MEDICINAL DROPS
IT8719390A0 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AKZO NOBEL N.V., ARNHEIM/ARNHEM, NL

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL